Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 3/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1224364 | 1.00 | MEN1 (0.45) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL2749935 | 1.00 | MEN1 (0.45) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL570033 | 0.88 | MEN1 (0.50) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL28118520 | 0.84 | SYK (0.36) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL13960156 | 0.83 | MEN1 (0.46) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL5352030 | 0.83 | MEN1 (0.46) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL16379307 | 0.83 | MEN1 (0.46) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL1222350 | 0.83 | TDP1 (0.49) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL1222348 | 0.83 | TDP1 (0.49) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL2369074 | 0.83 | MEN1 (0.46) | MEN1GAAKMT2ATDP1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| EP-2915813-B1 | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD (CH) | 2017-02-01 | — | — | EP | disclosed |
| EP-2915813-A1 | Oxazolidinone antibiotics | Actelion Pharmaceuticals Ltd. (CH) | 2015-09-09 | — | — | EP | disclosed |
| EP-2905283-A1 | Oxazolidinone antibiotics | Actelion Pharmaceuticals Ltd. (CH) | 2015-08-12 | — | — | EP | disclosed |
| CN-101679415-B | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD | 2013-07-31 | — | — | CN | disclosed |
| CN-102746297-A | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD | 2012-10-24 | — | — | CN | disclosed |
| CN-102746296-A | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD | 2012-10-24 | — | — | CN | disclosed |
| US-8217029-B2 | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD (CH) | 2012-07-10 | — | — | US | disclosed |
| US-20110039823-A1 | OXAZOLIDINONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-02-17 | — | — | US | disclosed |
| CN-101679415-A | oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD | 2010-03-24 | — | — | CN | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039823-A1 | OXAZOLIDINONE ANTIBIOTICS | OXA1L, XDH, UBE2D3 | MEN1 1471/4885GAA 1263/4885KMT2A 3162/4885 |
| US-11077101-B1 | Compounds and methods of use | XDH, F12, LPXN | MEN1 182/4885GAA 592/4885KMT2A 3722/4885 |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | XDH, F12, LPXN | MEN1 182/4885GAA 592/4885KMT2A 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.